Citation

Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U, Schäfer M, Ince S, Mumberg D, Scholz A, Izumi R, Hwang S, von Nussbaum F.: Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. J Med Chem, Volume 64 (15), 2021

Authors

Bohlmann R, Böhnke N, Bömer U, Briem H, Denner K, Hwang S, Ince S, Izumi R, Kosemund D, Lienau P, Lücking U, Mumberg D, Schäfer M, Scholz A, Siemeister G, Terebesi I, von Nussbaum F.

Journal

J Med Chem

Year

2021

DOI

10.1021/acs.jmedchem.1c01000

PubMed

34264057

Machine-readable

REST APIRDF